Long-acting Local Vaginal Cuff Anesthesia Following Hysterectomy (LAVA)
Long-acting Local Vaginal Cuff Anesthesia Following Hysterectomy: LAVA Trial
The purpose of this study is to compare recovery unit and post operation day (POD) 1 pain score in women following elective robotic assisted TLH (RA-TLH) for benign indication with and without local vaginal cuff injection of short acting bupivacaine and long acting Exparel, to evaluate postoperative pain management and control by assessing the amount and frequency of NSAIDS and opioids taken and to assess bleeding, vaginal discharge and or vaginal dehiscence at the postoperative follow up visit.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Asha B Bhalwal, MD
- Telefonnummer: (713) 566-4605
- E-post: Asha.B.Bhalwal@uth.tmc.edu
Studer Kontakt Backup
- Navn: Aya Sasson Mohr
- Telefonnummer: (713) 500-6412
- E-post: Aya.MohrSasson@uth.tmc.edu
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- The University of Texas Health Science Center, Houston
-
Ta kontakt med:
- Asha B Bhalwal, MD
- Telefonnummer: (713) 566-4605
- E-post: Asha.B.Bhalwal@uth.tmc.edu
-
Ta kontakt med:
- Aya Sasson Mohr
- Telefonnummer: (713) 500-6412
- E-post: Aya.MohrSasson@uth.tmc.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- at least 66.5kg weight
- elective Robotic assisted (RA) Total Laparoscopic Hysterectomy (TLH) for benign indications at Memorial Hermann Hospital Texas Medical Center, Memorial Hermann Hospital Cypress and Memorial Hermann Hospital Greater Heights.
Exclusion Criteria:
- Combined operation or alternative approach
- inpatient overnight admission
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Styre
|
In addition to the Laparoscopic Transversus Abdominis Plane (TAP) Block, participants will get will get vaginal cuff infiltration with 20 cc of injectable NS at the end of the procedure. |
|
Eksperimentell: Combined Bupivacaine and Exparel
|
In addition to the Laparoscopic Transversus Abdominis Plane (TAP) Block, participants will receive 20 cc of a mixture of 40 cc of short term 0.25% bupivacaine hydrochloride and long term 20 mL of Exparel® (266 mg/20 mL) mixed with 100cc of normal saline (total amount 160 cc) to the vaginal cuff using William's cystoscopy needle. The mixture will be infiltrated evenly at the uterosacral ligament with care (10 cc on each uterosacral ligament) taken to distribute the injection across the full length of the cuff at the end of the procedure. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in pain as assessed by the visual analog scale (VAS)
Tidsramme: 4-6 hours post operation, postoperative day 1, postoperative day 3
|
Pain will be scored from 1-10 , higher number indicating more pain |
4-6 hours post operation, postoperative day 1, postoperative day 3
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in level of pain control achieved as assessed by the amount of nonsteroidal anti-inflammatory drugs (NSAIDs) needed
Tidsramme: 2-week and 6- week follow up
|
2-week and 6- week follow up
|
|
|
Change in level of pain control achieved as assessed by the frequency of NSAIDS needed
Tidsramme: 2-week and 6- week follow up
|
2-week and 6- week follow up
|
|
|
Change in level of pain control achieved as assessed by the amount of opioids needed
Tidsramme: 2-week and 6- week follow up
|
2-week and 6- week follow up
|
|
|
Change in level of pain control achieved as assessed by the frequency of opioids needed
Tidsramme: 2-week and 6- week follow up
|
2-week and 6- week follow up
|
|
|
Change in level of bleeding as assessed by the volume of blood loss reported by the surgeon
Tidsramme: 2-week and 6- week follow up
|
2-week and 6- week follow up
|
|
|
Change in presence of vaginal dehiscence
Tidsramme: 2-week and 6- week follow up
|
This will be categorically reported as a yes or no answer |
2-week and 6- week follow up
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Asha B Bhalwal, MD, The University of Texas Health Science Center, Houston
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HSC-MS-26-0008
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .